Literature DB >> 28420047

Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years.

M Taraborelli1, I Cavazzana1, N Martinazzi2, M Grazia Lazzaroni2, M Fredi1, L Andreoli2, F Franceschini1, A Tincani1,2.   

Abstract

Objective The aim of this study was to determine the prevalence, predictors and progression of organ damage in a monocentric cohort of systemic lupus erythematosus patients with a long follow-up. Organ damage was assessed by the Systemic Lupus International Collaborating Clinics Damage Index one year after diagnosis and every five years. Disease activity was measured by the systemic lupus erythematosus disease activity index (SLEDAI)-2K at the beginning of the follow-up. Univariate and multivariable analyses were used to detect items associated with damage. A total of 511 systemic lupus erythematosus patients (92% females, 95% Caucasian), prospectively followed from 1972 to 2014, were included. Results After a mean disease duration of 16 years (SD: 9.5) and a mean follow-up of 12.9 years (SD: 8.8), 354 patients (69.3%) had accrued some damage: 49.7% developed mild/moderate damage, while 19.5% showed severe damage. Damage was evident in 40% of 511 patients one year after diagnosis, and its prevalence linearly increased over time. Longer disease duration, higher SLEDAI, severe Raynaud's, chronic alopecia and cerebral ischaemia were significantly associated with organ damage. No associations between damage and autoantibodies, including anti-dsDNA, anti-Sm or antiphospholipid antibodies, were observed. Anyway, antiphospholipid syndrome and anticardiolipin antibodies predicted the development of neuropsychiatric damage. The ocular, musculoskeletal and neuropsychiatric systems were the most frequently damaged organs, with a linear increase during follow-up. Conclusion A high rate of moderate and severe damage has been detected early in a wide cohort of young lupus patients, with a linear trend of increase over time. Disease activity and long duration of disease predict damage, while antiphospholipid antibodies play a role in determining neuropsychiatric damage.

Entities:  

Keywords:  Systemic lupus erythematosus; antiphospholipid antibodies; damage; disease activity; neuropsychiatric damage

Mesh:

Substances:

Year:  2017        PMID: 28420047     DOI: 10.1177/0961203317693096

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  17 in total

1.  Predictors of damage accrual in systemic lupus erythematosus: a longitudinal observational study with focus on neuropsychological factors and anti-neuronal antibodies.

Authors:  Milena Mimica; Ignacio Barra; Rocío Ormeño; Patricia Flores; Jorge Calderón; Oslando Padilla; Marcela Bravo-Zehnder; Alfonso González; Loreto Massardo
Journal:  Clin Rheumatol       Date:  2019-07-31       Impact factor: 2.980

2.  2019-EULAR/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus.

Authors:  Carlos E Insfrán; Nadia E Aikawa; Clovis A Silva; Eloisa Bonfa; Sandra G Pasoto; Dilson M N Filho; Francisco F C Formiga; Ana C Pitta; Eduardo F Borba; Carolina T Ribeiro
Journal:  Clin Rheumatol       Date:  2021-11-16       Impact factor: 2.980

3.  Real-world data on vitamin D supplementation and its impacts in systemic lupus erythematosus: Cross-sectional analysis of a lupus registry of nationwide institutions (LUNA).

Authors:  Keigo Hayashi; Ken-Ei Sada; Yosuke Asano; Yu Katayama; Keiji Ohashi; Michiko Morishita; Yoshia Miyawaki; Haruki Watanabe; Takayuki Katsuyama; Mariko Narazaki; Yoshinori Matsumoto; Nobuyuki Yajima; Ryusuke Yoshimi; Yasuhiro Shimojima; Shigeru Ohno; Hiroshi Kajiyama; Kunihiro Ichinose; Shuzo Sato; Michio Fujiwara; Jun Wada
Journal:  PLoS One       Date:  2022-06-29       Impact factor: 3.752

4.  Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort.

Authors:  Maria Gerosa; Lorenzo Beretta; Giuseppe Alvise Ramirez; Enrica Bozzolo; Martina Cornalba; Chiara Bellocchi; Lorenza Maria Argolini; Luca Moroni; Nicola Farina; Giulia Segatto; Lorenzo Dagna; Roberto Caporali
Journal:  J Clin Med       Date:  2022-06-22       Impact factor: 4.964

5.  Adverse Perinatal Outcomes Before and After Diagnosis of Systemic Lupus Erythematosus Among African American Women.

Authors:  Meghan Angley; Carolyn Drews-Botsch; Tené T Lewis; Martina Badell; S Sam Lim; Penelope P Howards
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-04-05       Impact factor: 5.178

Review 6.  Update on Antiphospholipid Syndrome: Ten Topics in 2017.

Authors:  Ilaria Cavazzana; Laura Andreoli; Maarteen Limper; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2018-03-15       Impact factor: 4.592

7.  Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort.

Authors:  Chiara Tani; Roberta Vagelli; Chiara Stagnaro; Linda Carli; Marta Mosca
Journal:  Lupus Sci Med       Date:  2018-02-27

8.  Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.

Authors:  N Groot; D Shaikhani; Y K O Teng; K de Leeuw; M Bijl; R J E M Dolhain; E Zirkzee; R Fritsch-Stork; I E M Bultink; S Kamphuis
Journal:  Arthritis Rheumatol       Date:  2019-02       Impact factor: 10.995

9.  Analysis of multiple organ damage and clinical immunological characteristics in systemic lupus erythematosus patients with hematologic involvement.

Authors:  Liming Tan; Yonglei Zhao
Journal:  Int J Med Sci       Date:  2021-05-01       Impact factor: 3.738

Review 10.  Global epidemiology of systemic lupus erythematosus.

Authors:  Megan R W Barber; Cristina Drenkard; Titilola Falasinnu; Alberta Hoi; Anselm Mak; Nien Yee Kow; Elisabet Svenungsson; Jonna Peterson; Ann E Clarke; Rosalind Ramsey-Goldman
Journal:  Nat Rev Rheumatol       Date:  2021-08-03       Impact factor: 32.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.